Dosing flexibility that suits you
 |
3-times-a-week 40 mg/mL1 |
 |
Once-daily 20 mg/mL1 |
The FDA approved Glatopa as a generic medicine that is therapeutically equal to and can be substituted for COPAXONE® (glatiramer acetate injection)2
Once-daily Glatopa 20 mg/mL was approved in April 2015, and 3-times-a-week Glatopa 40 mg/mL was approved in February 2018.
More days without injections is possible with 3-times-a-week dosing
With the 40 mg/mL dose, you only need to inject 3 times a week. That means you can plan injection-free weekends!
Indication
Glatopa® (glatiramer acetate injection) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Important Safety Information
Do not take Glatopa® if you are allergic to glatiramer acetate, mannitol, or any of the ingredients in Glatopa.
Some patients report a short-term reaction right after or within minutes after injecting glatiramer acetate. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain, fast heartbeat, anxiety, and trouble breathing. These symptoms generally appear within seconds to minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your healthcare provider right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your healthcare provider tells you to begin again.
Chest pain may occur either as part of the immediate post-injection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your healthcare provider if you experience chest pain that lasts for a long time or feels very intense.
A permanent indentation under the skin (lipoatrophy) or, rarely, necrosis at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your healthcare provider of any skin changes.
Liver problems, including liver failure, can occur with Glatopa. Call your healthcare provider right away if you have symptoms, such as: nausea, loss of appetite, tiredness, dark colored urine and pale stools, yellowing of your skin or the white part of your eye, bleeding more easily than normal, confusion, sleepiness.
The most common side effects in studies of glatiramer acetate injection are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of glatiramer acetate. For a complete list, ask your healthcare provider or pharmacist. Tell your healthcare provider about any side effects you have while taking Glatopa.
To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for Glatopa.
References
1. Glatopa Prescribing Information. Sandoz Inc. April 2022. 2. U.S. Department of Health & Human Services. Approved Drug Products With Therapeutic Equivalence Evaluations: 41st Edition. Washington, DC: US Department of Health and Human Services; 2021.
